Skip to main content
. 2015 Oct 27;2015:917567. doi: 10.1155/2015/917567

(a).

Scenarios Total cost ($) Total effectiveness (QALY) Incremental costs ($) Incremental effectiveness (QALY) ICER ($/QALY)
Cochrane (base-case)
 AZA 54,249.98 1.6367
 MMF 71,861.21 1.6434 17,611.23 0.0067 2,630,591.76
Subgroups
 ALMS
  AZA 55,959.12 1.6125
  MMF 72,619.05 1.6363 16,659.92 0.0238 700,001.12
 MAINTAIN
  AZA 54,527.62 1.6318
  MMF 72,511.65 1.6148 17,984.04 −0.0170 Dominated

QALY: quality-adjusted life-years; AZA: azathioprine; MMF: mycophenolate mofetil.